FinTechFunding

Orthocell: Receives new U.S. patent for CelGro

  • Regenerative medicine company Orthocell (OCC) has granted a new U.S. divisional patent for CelGro
  • The healthcare stock also focusses on regenerating mobility in patients by developing products for the repair of soft tissue injuries.
  • CelGro, a customisable collagen medical device manufactured by the company at its facility in WA using the company’s SMRT tissue engineering process
  • The new U.S. divisional patents expire in June 2033 and provide additional intellectual property to protect the CelGro platform
  • CelGro dental, recently renamed Striate+, the first product from the CelGro platform technology to gain U.S., European and Australian approval
  • Orthocell is down 1.79 per cent, trading at 55 cents

 

Previous article
BNP Paribas: Rolls out BENEtracker
Next article
Wells Fargo: Announces Pricing of Tender Offers by Its Wholly Owned Subsidiary
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

Former Royal Mint Executives Secure Backing for Precious Metals Trading Platform

New platform aims to modernize precious metals trading for investors.Highlights: Former Royal Mint executives launch a new trading...
FinTech

Coastal Bank Partners with Tempo to Strengthen Cross-Border Money Transfers

The partnership aims to enhance international money movement solutions.Highlights: Coastal Bank has partnered with Tempo for improved cross-border...
FinTech

Lloyds Accelerates Homebuying with Fully Digital Service

New platform aims to reduce waiting times for mortgage approvals.Highlights: Lloyds introduces a fully digital homebuying service.Service aims...
Blogs

AI in Fintech: Revolutionizing the Financial Industry

AI in fintech is changing how financial services operate. It's more than just a buzzword; it's a powerful...